🟥 Member Webinar : Hemophilia Alliance Hosts - HTC Preparation for ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) from BioMarin
2023-08-08 13:00 - 14:00 (America/New_York)
Date: Tuesday, August 8, 2023
Time: 1:00pm – 2:00pm ET

TITLE:
HTC preparation for ROCTAVIAN ™ (valoctocogene roxaparvovec-rvox)
OBJECTIVE:
Learn about eligibility testing, ordering, storing, handling and administering ROCTAVIAN
TARGET AUDIENCE:
HTC staff interested in learning about ROCTAVIAN’s clinical and logistical requirements
SPEAKER:

Henry Mead PhD, MBA, MPA
Senior Director, BioMarin Hemophilia North America Medical Affairs
Henry Mead has worked in medical affairs for over two decades in North America and globally. Over the last 15 years it has been his privilege to work closely with hemophilia researchers, clinical investigators, patient advocates, and hemophilia nurses. His experience includes leading medical affairs team’s ensuring they adhere to the principles of credible, accurate and balanced scientific dissemination of data to external customers. Additionally, identifying, vetting, and supporting investigator-initiated research and publishing relevant findings has been an important component of knowledge transfer activities.

🟦 Non-Member Event : NHF BDC 2023
2023-08-17 - 2023-08-19
Date: August 17th – 19th (National Harbor, MD)
Click here for info.

🟥 Member Webinar : Hemophilia Alliance Hosts - Simplifi 797 for Hemophilia Alliance member HTC pharmacies
2023-08-22 14:00 - 15:00
Date: Tuesday, August 22, 2023
Time: 2:00pm – 3:00pm ET

The webinar will review how to stay compliant with USP 797

SOP’s
Training
Competencies
Task Management
Reporting
Alerting
Elimination of Blind Spots

Please contact Mark Plencner at mark@hemoalliance.org with questions.

🟦 Non-Member Event : 2023 Partners Physician Academy
2023-09-18 - 2023-09-22
Date: September 18th – 22nd
Click here for info.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Case Discussion from Takeda on Adult Severe Type 3 von Willebrand Disease Patient
2023-09-20 13:00 - 14:00
Date: Wednesday, September 20, 2023
Time: 1:00pm – 2:00pm ET

TITLE:
Case Discussion: Adult Severe Type 3 von Willebrand Disease Patient
OBJECTIVE:
In case you missed it at the National Bleeding Disorders Foundation conference, join expert Dr. Jonathan Roberts, MD for an interactive discussion about managing patients who are living with von Willebrand Disease (VWD). Dr. Roberts will guide you through a VWD case-based experience, including reviewing treatment history and a treatment option for prophylaxis.
TARGET AUDIENCE:
Hematologists, nurses, pharmacists, and other stakeholders with medical credentials
SPEAKER:

Dr. Jonathan C. Roberts, MD
Dr. Roberts is the Associate Medical Director/Associate Research Director of Bleeding and Clotting Disorders Institute in Peoria IL. Dr. Roberts is also an Associate Professor of Pediatrics and Medicine at the University of Illinois College of Medicine.
His research areas of interest are in advancing novel laboratory assay development to improve the diagnosis of von Willebrand Disease (VWD) and enhancing individualized clinical management of hemophilia, VWD, and other rare bleeding and classical hematologic disorders.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Clinical Overview from Novo Nordisk - An injectable, extended half-life recombinant, glycopegylated factor VIII concentrate for Hemophilia A
2023-10-04 13:00 - 14:00
Date: Wednesday, October 4, 2023
Time: 1:00pm – 2:00pm ET

TITLE:
An injectable, extended half-life recombinant, glycopegylated factor VIII concentrate for Hemophilia A
OBJECTIVE:
Provide a clinical overview of Esperoct that supports prophylactic, on-demand and perioperative management indications in adults and children.
TARGET AUDIENCE:
All HTC Staff
SPEAKER:

Parin Chikani, PharmD, MBA
Medical Account Director, Novo Nordisk Inc
Parin Chikani, lives in the Chicagoland area and earned his Doctorate of Pharmacy degree from the University of Illinois at Chicago, College of Pharmacy and his MBA from Kellstadt Graduate School of Business. Before joining Novo Nordisk, Parin had been in the Pharmacy/Managed Care setting for over 15 years where he held many different roles and leadership positions within Pharmacy and Medical areas of the business. At Novo Nordisk, one of his roles and responsibilities is to ensure payors and clinicians are up-to-date on evidence based clinical and scientific information in the areas of Rare Diseases to help assist them with patient care.

🟥 Member Event : Fall Members Meeting
2023-10-08 - 2023-10-10 | The St. Anthony Hotel, San Antonio, 300 East Travis Street, San Antonio, TX, 78205, United States
Venue: The St. Anthony Hotel
Location: San Antonio, Texas

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

DRAFT AGENDA:

Oct. 8th – Welcome Reception @ 6pm
Oct. 9th – Breakfast @ 7:30am; Meeeting: 8:30am – 5:00pm; Group Dinner @ 6:30 pm
Oct. 10th – Breakfast @ 7:30am; Meeeting: 8:30am – 3:30pm

🟥 Member Webinar : Hemophilia Alliance Hosts - A Clinical Overview from Novo Nordisk - A Label Update on Rebinyn, (Coagulation Factor IX (Recombinant), GlycoPEGylated: FDA Approval for a Prophylaxis Indication for Persons with Hemophilia B
2023-10-12 13:00 - 14:00
Date: Thursday, October 12, 2023
Time: 1:00pm – 2:00pm ET

TITLE:
A Label Update on Rebinyn, (Coagulation Factor IX (Recombinant), GlycoPEGylated: FDA Approval for a Prophylaxis Indication for Persons with Hemophilia B
OBJECTIVE:
Provide a clinical review of Rebinyn that supports prophylaxis, on-demand and perioperative indication in adults and children
TARGET AUDIENCE:
All HTC Staff
SPEAKER:

Parin Chikani, PharmD, MBA
Medical Account Director, Novo Nordisk Inc
Parin Chikani, lives in the Chicagoland area and earned his Doctorate of Pharmacy degree from the University of Illinois at Chicago, College of Pharmacy and his MBA from Kellstadt Graduate School of Business. Before joining Novo Nordisk, Parin had been in the Pharmacy/Managed Care setting for over 15 years where he held many different roles and leadership positions within Pharmacy and Medical areas of the business. At Novo Nordisk, one of his roles and responsibilities is to ensure payors and clinicians are up-to-date on evidence based clinical and scientific information in the areas of Rare Diseases to help assist them with patient care.

🟦 Non-Member Event : ATHN Data Summit
2023-10-18 - 2023-10-20
Date: October 18th – 20th (Atlanta, GA)
Click here for info.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Clinical Overview and Update from Sanofi for Efanesoctocog Alfa, A High Sustained Factor VIII Therapy
2023-10-24 14:00 - 15:00
Date: Tuesday, October 24, 2023
Time: 2:00pm – 3:00pm ET

TITLE:
A Clinical Overview and Update from Sanofi for Efanesoctocog Alfa, A High Sustained Factor VIII Therapy
OBJECTIVES:

Highlighting both Efanesoctocog Alfa’s pediatric study, the XTEND-Kids data that were presented at ISTH 2023, as well as an observational study of patients who switched from current therapy to Efanesoctocog Alfa prophylaxis.
Highlighting available lab monitoring program available to your centers.

TARGET AUDIENCE:
All HTC Staff
SPEAKER:

Nancy Epp, PharmD, BCACP
Nancy Epp is a Senior Medical Science Liaison with Sanofi. She supports the Sanofi hemophilia A and B portfolio to provide up-to-date scientific data to healthcare providers. Nancy is based in Houston, Texas, and can be reached by email at Nancy.Epp@sanofi.com.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Pfizer - Case Studies of Using BeneFix® (Coagulation Factor IX [Recombinant]) in Different Hemophilia B Patient Populations in an Evolving Treatment Landscape – Is There More to the Story?
2023-11-07 14:00 - 15:00
Date: Tuesday, November 7, 2023
Time: 2:00pm – 3:00pm ET

TITLE:
Case Studies of Using BeneFix® (Coagulation Factor IX [Recombinant]) in Different Hemophilia B Patient Populations in an Evolving Treatment Landscape – Is There More to the Story?
SPEAKER:

Doris Quon, MD
Medical Director of the Orthopaedic Hemophilia Treatment Center at the Luskin Orthopaedic Institute for Children in Los Angeles, California

🟥 Member Webinar : Hemophilia Alliance Hosts - A Discussion from Genentech About Subcutaneous Prophylaxis Treatment for Hemophilia A
2023-11-09 13:00 - 14:00
Date: Thursday, November 9, 2023
Time: 1:00pm – 2:00pm ET

TITLE:
Learn More About Subcutaneous Prophylaxis Treatment for Hemophilia A: A Discussion on the Latest Data and Patient Management
DESCRIPTION:
Please join us for an engaging webinar led by Ketna Mistry, MD who will be sharing information on patients with hemophilia A with a subcutaneous prophylaxis including the latest clinical data. Ther presentation will include pivotal efficacy and safety data, joint health data, data in infants, and an overview of real-world experience. Be sure to bring your questions to have them answered during the Q&A following the program!
SPEAKER:

Ketna Mistry, MD
Medical Director, Hematology & Rare Blood Disorders, U.S. Medical Affairs; Genentech
Dr. Mistry has 25 years of experience in her medical career, as a physician caring for patients and teacher at Emory University, a researcher at CDC, and currently as a medical director at Genentech. She completed medical school at Tulane University and graduated with honors from UCLA for her bachelor’s degree in psychobiology. She completed her internship and residency in pediatrics at University of Texas in Houston. She is passionate about teaching and sharing information so that patients and providers can make the best informed decision for their care.

🟥 Member Event : Physicians & Business Administrators Meeting
2023-11-10 - 2023-11-12 | The Portofino Hotel & Marina, Redondo Beach, 260 Portofino Way, Redondo Beach, CA, 90277, United States
Location: Redondo Beach, California
Venue: The Portofino Hotel & Marina

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727.688.2568.

DRAFT AGENDA
Friday: 8 am to 5 pm
For Business Administrators

Alliance Services – an overview of what is offered by Hemophilia Alliance
340B Refresher – Basic overview with answers to targeted questions
Understanding Medicaid & Medicare – A look at the public payers and changes
HANS – Why it’s important to have payer contracts
Why we need National Patient Org
Advocacy – Threats and Opportunities for HTCs
Understanding GPO contracts
Running an HTC pharmacy – Having a Strategic Plan
Legal Discussion – Understanding the challenges

6 pm – Dinner
Saturday: 8 am to 12:30 pm
Business Course
Sunday: 8 am to 12:30 pm
For Clinical Providers

Strengths: Leadership – How to work within an HTC
Weakness: Relationships – How to work within a larger institute
Opportunities: Risk – Going Independent
Threats: Planning – Strategic Plan

🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar on Hemgenix Real World Learnings from CSL Behring
2023-11-13 13:00 - 14:00
Date: Monday, November 13, 2023
Time: 1:00pm – 2:00pm ET

TITLE:
Hemgenix Real World Learnings
SPEAKER:

Vidhi Desai, MD
Senior Medical Director, Coagulation
North America Medical Affairs
Vidhi Desai joined CSL Behring in 2018 as Therapeutic Area Head, Director Medical Affairs for Coagulation Products in North America, providing strategic and tactical medical leadership for Idelvion®, Afstyla® and Humate-P®, contributing to key operational and cross-functional projects as a member of the Medical Affairs leadership team.
Prior to joining CSL Behring, Vidhi worked as an attending hematologist at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, focusing primarily on benign hematologic disorders.
Vidhi earned her Doctor of Medicine at New York Medical College and completed her internal medicine and hematology/oncology training at Rutgers Robert Wood Johnson Medical School in New Brunswick, NJ.

🟥 Member Webinar : Hemophilia Alliance Hosts - An Informational Session from Bayer - Clinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi®
2023-11-17 13:00 - 14:00
Date: Friday, November 17, 2023
Time: 1:00pm – 2:00pm ET

TOPIC:
Clinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi®
OVERVIEW:
This session includes key information about Jivi including, safety and efficacy data from the clinical trials, step-wise dosing and Jivi RWE Data from HEM-POWR, a multinational,open-label, prospective, non-interventional, multicenter cohort study of Jivi®.
There will also be a review of the Q4 2023 340B pricing for the Bayer Hemophilia A portfolio under the Hemophilia Alliance Contract.
TARGET AUDIENCE:
All HTC Staff
SPEAKER:

Mark T. Reding, MD.
Director, Center for Bleeding and Clotting Disorders
Professor of Medicine, Division of Hematology, Oncology, and Transplantation
University of Minnesota

For additional important risk and use information, please see the full Prescribing Information for Jivi.
You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from HEMA Biologics - A different treatment option for Inhibitor patients
2023-11-27 13:00 - 14:00
Date: Monday, November 27, 2023
Time: 1:00pm – 2:00pm ET

TITLE:
A different treatment option for Inhibitor patients
OBJECTIVE:
This presentation will provide an overview of inhibitors and explore the efficacy, safety, tolerability, clinical development, and reasons to consider a different treatment option.
TARGET AUDIENCE:
All HTC Staff
SPEAKER:

Guy Young, MD.
Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory Cancer and Blood Disorders Institute Children’s Hospital Los Angeles
Professor of Pediatrics, University of Southern California Keck School of Medicine

🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from Takeda - Overview of Adzynma (rADAMTS13) Prescribing Information
2023-11-29 13:00 - 14:00
Date: Wednesday, November 29, 2023
Time: 1:00pm – 2:00pm ET

TITLE:
Overview of Adzynma (rADAMTS13) Prescribing Information
OBJECTIVE:
Inform on the new approval and prescribing information of Adzynma indicated for prophylactic and on-demand use for patients with congenital TTP.
TARGET AUDIENCE:
Hematologists, NPs, nurses, pharmacists
SPEAKER:

Ali Mokdad, MD, PhD, MBA, Medical Director, Takeda

🟦 Non-Member Event : ASH Annual Meeting
2023-12-09 - 2023-12-12
Date: December 9th – 12th (San Diego, CA & Virtual)
Click here for info.

🟥 Member Event : 2024 Hemophilia Alliance Board Retreat
2024-01-07 - 2024-01-09
Date: January 7 – 9
Location: Dallas, TX

🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from Takeda - Real-world Characterization of Female Hemophilia A Carriers in the US
2024-01-23 13:00 - 14:00
Date: Tuesday, January 23, 2024
Time: 1:00pm – 2:00pm ET

TITLE:
Real-world Characterization of Female Hemophilia A Carriers in the US
OBJECTIVE:
Summarize recently published real-world data on Female Hemophilia A Carriers in the US, including clinical and healthcare resource utilization information.
TARGET AUDIENCE:
Hematologists, NPs, nurses, pharmacists
SPEAKER:

Jorge Caicedo, MD, Sr. Medical Director, Takeda

🟥 Member Event : 2024 Pharmacist CE Conference
2024-01-24 - 2024-01-26 | The Limited Hotel, 425 Meeting Street, Charleston, SC, 29403, United States
Date: January 24 – 26
Location: Charleston, South Carolina

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Event : 2024 Linda Gammage Social Worker Conference
2024-02-28 - 2024-03-01 | Renaissance New Orleans Arts Warehouse District Hotel, 700 Tchoupitoulas Street, New Orleans, LA, 70130, United States
Date: Febuary 28 – March 1
Location: New Orleans, LA

Please contact Jeff Amond with any questions regarding this registration at amond@hemoalliance.org or 608-206-3132.

🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from BD SUMHAC - Advocating for Access to Behavioral Health Treatment for the Bleeding Disorders Community
2024-03-05 13:00 - 14:00
Date: Tuesday, March 5, 2024
Time: 1:00pm – 2:00pm ET

TITLE:
Advocating for Access to Behavioral Health Treatment for the Bleeding Disorders Community
WEBINAR OBJECTIVE:
This presentation will educate HTC providers about the barriers to access to inpatient and residential mental health and substance use treatment facilities for people with bleeding disorders. It will provide tools that HTC providers can use to facilitate access to behavioral health treatment for their patients and resources for responding to denials. Finally, it will briefly introduce the federal and state advocacy work of the Bleeding Disorders Substance Use and Mental Health Access Coalition, and share opportunities for provider involvement.
SPEAKERS:

Kate Bazinsky, MPH – Chair, Bleeding Disorders Substance Use and Mental Health Access Coalition
Emily Wheat, PhD – Psychologist, University of Colorado Hemophilia Treatment Center
Jen Feldman, RN, MSN – Nurse Coordinator, University of Massachusetts Memorial Hemophilia Treatment Center
Lucy Ramirez, LCSW – Social Worker, Rush University Medical Center Hemophilia Treatment Center

🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from Pfizer - Exploring the Science and Possibilities of Gene Therapy in Hemophilia
2024-03-14 13:00 - 14:00
Date: Thursday, March 14, 2024
Time: 1:00pm – 2:00pm ET

TITLE:
Exploring the Science and Possibilities of Gene Therapy in Hemophilia
WEBINAR OVERVIEW:
By attending this webinar, you will discover the scientific approach of gene therapy, understand gene therapy objectives for patients with hemophilia, and explore the shared decision-making process to accompany your patients in their decision journey.
SPEAKER:

Nathan T. Connell, MD, MPH,
Boston Hemophilia Center
Brigham and Women’s Hospital and Harvard Medical School
Dr. Nathan Connell is Chief of Medicine at Brigham and Women’s Faulkner Hospital, Vice Chair of Medicine at Brigham and Women’s Hospital, Associate Director of the Boston Hemophilia Center, and Associate Professor of Medicine at Harvard Medical School. In addition to his work defining the field of systems-based hematology, he co-chaired the ASH ISTH NHF WFH Guidelines on the Diagnosis and Management of von Willebrand disease.

🟥 Member Event : 2024 New HTC Staff Orientation
2024-03-25 - 2024-03-27
Date: March 25 – 27
Location: TBD
PLEASE NOTE REGISTRATION FOR THIS MEETING WILL CLOSE ON FEBRUARY 9, 2024.

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟦 Non-Member Event : THSNA 2024 Thrombosis & Hemostasis Summit of North America
2024-04-03 - 2024-04-06
Date: April 3rd (Pre-Summit Workshops)
Date: April 4th – 6th (Chicago, IL & Virtual)
Click here for info.

🟥 Member Event : 2024 Spring Members Meeting & Hemophilia Alliance Hill Day
2024-04-15 - 2024-04-18
Date: April 15 – 18
Location: Washington, DC

Monday 4/15 – Welcome Reception
Tuesday 4/16 – Spring Members Meeting
Wednesday 4/17 – Spring Members Meeting, Hill Day Training and Joe’s Retirement Party
Thursday 4/18 – Hemophilia Alliance Hill Day

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from Genentech - Reinforcing 10+ years of clinical trial experience with a subcutaneous prophylaxis treatment
2024-05-07 14:00 - 15:00
Date: Tuesday, May 7, 2024
Time: 2:00pm – 3:00pm ET

TITLE:
Reinforcing 10+ years of clinical trial experience with a subcutaneous prophylaxis treatment, including the latest data in infants
WEBINAR OBJECTIVE:
Dr. Mike Silvey will share his perspective on managing patients with hemophilia A using a subcutaneous prophylactic treatment. The presentation will include the pivotal efficacy and safety data that is the foundation of the ongoing clinical trial program in patients with and without FVIII inhibitors, including an overview of real-world experience. Dr. Silvey will share updates from the latest trial in infants and previously untreated patients. The webinar will feature brain teasers, and showcase social media that’s engaging the hemophilia community and polls. Q&A session will follow the program.
SPEAKER:

Michael Silvey, DO
HTC Director – Children’s Mercy HTC, Kansas City, MO.
Associate Professor of Pediatrics – University of Missouri-Kansas City School of Medicine.
SPEAKER’S BIO:
Michael Silvey, DO, is an Associate Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine and the Associate Director of the Kansas City Regional Hemophilia Treatment Center at Children’s Mercy Hospital in Kansas City, Missouri. He received his medical degree from The Chicago College of Osteopathic Medicine. He completed his general pediatrics residency at the University of Texas Health Science Center-San Antonio and his pediatric hematology/oncology fellowship at Children’s Mercy Hospital in Kansas City, Missouri. His primary clinical and research interests are hemophilia, inherited platelet function disorders, and the coagulation system in patients with congenital heart disease as well as patients need ECMO. Dr. Silvey serves as a primary investigator for several research studies involving both bleeding and clotting disorders. In addition to enjoying taking care of pediatric bleeding disorder patients, he also likes to spend lots of time with his wife and two children and getting out on the golf course.

🟥 Member Webinar : Hemophilia Alliance Presents - Hemophilia Alliance Network Services/Emerging Therapy Solutions
2024-05-14 14:00 - 15:00
Date: Tuesday, May 14, 2024
Time: 2:00pm – 3:00pm ET

TITLE:
Hemophilia Alliance Network Services/Emerging Therapy Solutions
A Gene Therapy Payer Contract
WEBINAR DESCRIPTION:
The past twelve to eighteen months have been landmark times for gene therapy treatments for individuals with bleeding disorders. While the third party payers, reinsurers and prescription benefit plans have begun forming strategies for benefit plan coverage, pricing, patient qualifications and follow up reporting. Hemophilia Alliance Network Services (HANS) has been hard at work arranging for adequate contractual arrangements with important entities influencing Payor behavior and strategies for the use of Gene Therapy. The HANS goal was to create relationships with entities that could offer acceptable contractual terms but importantly influence the common prior authorization process to provide a clear path for delivery of the product, provision of the service to Hemophilia Treatment Center (HTC) patients, and subsequent confidence in the payment for this high-cost therapy.
HANS is pleased to announce that it has executed an Agreement with Emerging Therapy Solutions (ETS) effective January 1, 2024. Emerging Therapy Solutions® (ETS), an industry leader in providing cutting-edge services to help payers and other risk-bearing entities prepare for the accelerating growth in cell and gene therapies and other high-cost, complex treatments. This webinar will provide a high-level overview from HANS leadership regarding the Agreement with ETS as well as how HTCs can gain access to this Agreement. HANS will ask the leadership from ETS to describe the business model and services they provide, the ETS customer base and provide important information on how to HTCs can intersect with ETS to obtain necessary approvals for gene therapy treatments for qualified patients. During this one-hour webinar you will hear important details on the authorization process, clinical review and administrative details that provide a clearer path to benefit coverage and payment for HTC patients rather than the time-consuming process of single case agreements with payors that many HTCs have experienced thus far.
This webinar is available to ALL Hemophilia Treatment Centers that are members of the Hemophilia Alliance, it is NOT restricted to participating members of the Hemophilia Alliance Network Services Agreements. If an HTC is not a HANS member today and wishes to join HANS to access the ETS agreement , please reach out to your Member and Community Relations Team Member who will assist you. Administrators, Finance team members, Pharmacists and Physicians are ideal candidates to attend this webinar. However, it is open to any interested employee of member HTCs.
SPEAKERS & BIOs:

Roland Lamy, Jr. – Vice President of Payer Relations
Roland Lamy has held a variety of leadership positions in the healthcare industry including sales management, underwriting, employee benefit and rate development, hospital and physician negotiations and contracting, and government programs oversight and business management. Click here to learn more about Roland…

Zack Duffy – Director of Member & Community Relations
Most recently, Zack Duffy was the Program Administrator for The Hemophilia Center at Oregon Health & Science University (OHSU) overseeing the administrative and business functions of the clinic and pharmacy. He started with the Factor Program at The Hemophilia Center in 2013, when it was a 340B physician dispense model. In 2017, he led the transition from a physician dispense to a pharmacy dispensing model. Click here to learn more about Zack…

🟥 Member Event : 2024 Physical Therapists CE Conference
2024-05-15 - 2024-05-17 | Search
Date: May 15 – 17
Location: Aurora, CO

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
